December 2023
1. MARGOT N, Pennetzdorfer N, Naik V, Rhee M, et al
   Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA.
   Antivir Ther. 2023;28:13596535231220754.
   

   >> Share

   
   August 2022
2. BELLO G, Kagoli M, Chipeta S, Auld A, et al
   Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi.
   Antivir Ther. 2022;27:13596535221121225.
   

   >> Share

   
   June 2022
3. MUSENGIMANA G, Tuyishime E, Kiromera A, Malamba SS, et al
   Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
   Antivir Ther. 2022;27:13596535221102690.
   

   >> Share

   
   April 2022
4. ROEDIGER R, Smyth EK, Dieterich D
   Adefovir for lamivudine-resistant hepatitis B.
   Antivir Ther. 2022;27:13596535211067605.
   

   >> Share

   
   May 2021
5. SCHEIBE K, Urbanska A, Jakubowski P, Hlebowicz M, et al
   Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
   Antivir Ther. 2021;26.
   

   >> Share

   
   October 2020
6. JIA J, Shang J, Tang H, Jiang J, et al
   Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.
   Antivir Ther. 2020 Oct 22. doi: 10.3851/IMP3372.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share